mfn-cus-2019 | Nanologica

Renewed agreement with crop protection company

9 December, 2019

Nanologica has renewed the agreement with the crop protection company that during the year has performed field studies based on Nanologica’s formulation of an active ingredient for crop protection. The purpose of the new agreement is to further optimize this formulation, as well as formulating other active ingredients. The value of the agreement amounts to approx. TSEK 948 (€ 90 000) distributed over the first half of 2020. In September 2017 Nanologica entered into an agreement

Nanologica’s collaboration project prolonged

17 October, 2019

The agreement between Nanologica and AstraZeneca for the evaluation of Nanologica’s pending patented technology applied to AstraZeneca materials has been extended. The evaluation of the NLAB Silica™ drug delivery platform started at the beginning of 2019. It has now been decided to prolong and expand this collaboration project. The extension of the project is regulated under the same feasibility agreement as signed in January 2019. This extension will further evaluate Nanologica’s platform for the purpose

Start of process for preparing investigational medication for NIC-001

2 October, 2019

English translation NIC-001 is Nanologica’s sublingual formulation of metoclopramide for treating gastroparesis patients. The process for preparing investigational medication for the clinical study has now started. NIC-001 is a sublingual formulation of metoclopramide, which means it is a tablet that is put under the tongue where it dissolves. The drug is absorbed through the mucous membrane beneath the tongue and diffuses into the capillaries after which it enters the venous circulation without passing the

Large potential for Nanologica’s product for the treatment of gastroparesis

3 September, 2019

After regulatory investigations and an extended market analysis, Nanologica advances the project NIC-001 towards clinical phase IIa. The market analysis shows good market potential for the product. Nanologica has, after careful considerations, decided to focus the clinical development program for the treatment of gastroparesis to the North American market. The decision was based on an extended market analysis of the American market carried out by Informa Pharma Consulting on behalf of Nanologica. In-depth interviews with

Start of large-scale production of silica

20 August, 2019

Large-scale production of Nanologica’s silica has now started at the contract manufacturer Sterling Pharma Solutions Ltd. in Newcastle, United Kingdom. A framework agreement was signed last year, where the terms for starting large-scale production were dependent on Nanologica securing a customer contract for the purchase of silica. Production has now started at Sterling, following the signing in July this year with Chinese Yunbo Technology for a long-term purchase order of silica for preparative chromatography. Sterling

Nanologica starts business within preparative chromatography with profitable agreement

2 July, 2019

Nanologica enters into an agreement with Chinese Yunbo Technology (Beijing) Co. for the delivery of preparative chromatography media to a value of approximately MUSD 14. With the agreement as foundation, Nanologica starts large scale production of silica at the contract manufacturer Sterling Pharma Solutions Ltd. The agreement between Nanologica and Yunbo Technology (Beijing) Co. stretches over six years (2021–2026) and means that Nanologica shall deliver media for preparative chromatography to a value of approximately MUSD

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.